Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
Cell Therapy News
Cell Therapy News is an online resource dedicated to sharing the latest cell therapy, gene therapy, and regenerative medicine research.
Subscribe|Follow Us On
First Patient in Arizona Treated with New Immune-Cell Therapy at HonorHealth Research Institute
[HonorHealth Research Institute (EurekAlert)] A patient with synovial sarcoma, a soft-tissue cancer that usually occurs in the large joints of the arms and legs, is the first in Arizona treated with a new immune-cell-therapy known as TECELRA at the HonorHealth Research Institute.
IL-36γ Armored CAR T Cells Reprogram Neutrophils to Induce Endogenous Antitumor Immunity
[Cancer Cell] Researchers reported that IL-36γ armored CAR T cells eradicate primary solid tumors and enable rejection of rechallenged antigen-negative tumors.
Cis- and Trans-Binding Chimeric Costimulatory Receptors Enhance T-Cell Fitness and Tumor Control
[Cellular & Molecular Immunology] Investigators characterized the molecular requirements for a platform enabling costimulation in engineered T cells on the basis of dual targeting of a single antigen via a TCR and a chimeric costimulatory receptor.
ZAP327 Signaling Domain-Driven Chimeric Antigen Receptor Generates Robust and Long-Term Antitumor Immunity in Mouse Models
[Science Translational Medicine] Scientists reported the construction of CARs with a ZAP70-derived signaling domain (ZAP327) that enhances therapeutic antitumor activity with increasing in vivo T cell persistence.
Personalized CRISPR Knock-in Cytokine Gene Therapy to Remodel the Tumor Microenvironment and Enhance CAR T Cell Therapy in Solid Tumors
[Nature Communications] The authors presented a gene-therapeutic strategy that enables localized remodelling of the tumor microenvironment via tumor-intrinsic cytokine expression.
mRNA Vaccine Developed for Sequential Selective Organ-to-Cell Targeting of Glioma
[Nature Communications] Researchers synthesized a library of meta/ortho/para-ionizable lipidoids and prepare three-component lipid nanoparticles without PEG-lipids.
Gene-Corrected Regulatory T Cell Therapy for IL2RA Deficiency
[Molecular Therapy] Investigators introduced a novel therapeutic approach involving ex-vivo generation of gene-corrected autologous regulatory T cells.
Sodium Valproate Drives Propionylation-Mediated Epigenetic Reprogramming to Enhance Mesothelin CAR-T Cell Therapy in Solid Tumors
[Molecular Therapy] Scientists combined CAR-T therapy with sodium valproate (VPA), a clinically approved histone deacetylase inhibitor. VPA-treated CAR-T cells (CAR-T+VPA) showed improved cytotoxicity, reduced exhaustion, and enhanced tumor infiltration.
Dual-Targeted Ping-Pong CAR T Cells: Leveraging Peripheral Expansion to Improve Solid Tumor Immunotherapy
[Proceedings of The National Academy of Sciences of The United States of America] Researchers engineered dual-targeted and dual-costimulated CAR T cells that recognize CD19+ B cells, thereby promoting peripheral expansion and increasing the pool of solid tumor-directed CAR T cells available for tumor infiltration without the need for lymphodepletion.
Enhanced Anti-Liver Tumor Efficacy of Chimeric Antigen Receptor-T Cells via SATB1 Modulation
[Cell Death & Disease] Scientists identified SATB1—a genome organizer regulating chromatin architecture—as a key suppressor of CAR-T cell exhaustion.
Redefining Multiple Sclerosis with CAR-T Cell Therapy
[Molecular Therapy] The authors summarize recent advances in applying CAR-T cell therapy to multiple sclerosis, outline key lessons learned from oncology and other autoimmune diseases, and discuss future directions for establishing CAR-T cells as a transformative approach in neuroimmunology.
FDA Approves Marginal Zone Lymphoma CAR T Cell Treatment
[Memorial Sloan Kettering Cancer Center] The US FDA has approved a new therapy for marginal zone lymphoma: lisocabtagene maraleucel. The approval is based on results from a Phase II clinical trial led by Memorial Sloan Kettering Cancer Center hematologist-oncologist Dr. Lia Palomba.
Published since 2002, Cell Therapy News is our longest running online publication. Our editorial team curates the top publications, reviews, and news on in vivo gene therapy, cell therapy, and immunotherapy research. With over 15,000 subscribers and followers across our website, email newsletter, and Twitter feed, we are proud to facilitate the communication of cutting-edge cell therapy innovations.
